Actively Recruiting
Immune Defense Protein Impact On Respiratory Immune Outcomes
Led by Quantec Ltd · Updated on 2026-03-12
300
Participants Needed
1
Research Sites
34 weeks
Total Duration
On this page
Sponsors
Q
Quantec Ltd
Lead Sponsor
P
People Science, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
The primary goal of this study is to observe the impact of the IDP® Supplement on the duration and severity of upper respiratory symptoms in older individuals during the cold and flu season. Secondary aims include observing the product's effect on rescue medication use, quality of life, and overall tolerability. This is conducted as a consumer-driven, decentralized observational clinical research study in adults aged 60 or older, using self-reported measures and questionnaires completed at home via the Chloe App.
CONDITIONS
Official Title
Immune Defense Protein Impact On Respiratory Immune Outcomes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 60 years and older
- Experience upper respiratory symptoms (such as coughing, sneezing, congestion) at least 2-3 times during the cold/flu season
- Able to read and understand English
- Able to provide informed consent
- Able to use a personal smartphone and download the Chloe app
- Able to receive shipment of the product at a U.S. address
You will not qualify if you...
- Lack of personal smartphone or internet access, or unwillingness to download Chloe app
- Immunocompromised states including HIV/AIDS, advanced chronic hepatitis B or C, tuberculosis
- Cancer-related conditions such as leukemia, lymphoma, multiple myeloma, or metastatic cancer receiving chemotherapy
- Current immunosuppressive treatments including corticosteroids (≥20 mg/day prednisone for ≥2 weeks), biologics, calcineurin inhibitors, mTOR inhibitors, JAK inhibitors, chemotherapy or radiation therapy, or post-organ transplant anti-rejection medications
- History of solid organ or hematopoietic stem cell transplant
- Autoimmune or inflammatory diseases treated with immunosuppressants including rheumatoid arthritis, systemic lupus erythematosus, psoriasis, inflammatory bowel disease, multiple sclerosis
- Use of investigational therapies within 30 days prior to enrollment
- Known diagnosis of asthma or COPD
- Current alcohol or substance use disorder
- Medical conditions that may confound study outcomes or impact participation as judged by the investigator
- Daily use of cannabis or nicotine products
- Known allergy to milk products, sorbitol, or tablet ingredients
- Unlikely to comply with trial requirements or deemed unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
People Science, Inc.
Los Angeles, California, United States, 90045
Actively Recruiting
Research Team
N
Noah Craft, M.D., Ph.D
CONTACT
A
Azure Grant
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here